Company* |
Company | Type/Product Area | Terms/Details (Date) |
Amarin Corp. |
Anthony Clarke (inventor of technology) |
Amarin acquired rights to an oral formulation of apomorphine for use in treating Parkinson's disease |
Clarke invented the formulation prior to his hiring by Amarin; Clarke is entitled to up-front, milestone and royalty payments in the deal (5/17) |
KineMed Inc.* |
CMIC Co. Ltd. (Japan) |
Deal under which CMIC will will seek compounds within Japanese pharmaceutical firms for potential joint development |
KineMed will evaluate compounds selected by the contract research organization; it then may in-license or partner the agents; CMIC will have an option to become KineMed's partner in Japan (5/24) |
Lev |
Hannu Suomela (inventor of technology) |
Lev acquired exclusive rights to methods for producing plasma-derived intravenous immunoglobulin |
Terms of the deal were not disclosed (5/24) |
Rexahn |
Future Systems Ltd. (South Korea) |
Future Systems is getting rights to three Rexahn drug candidates in certain territories |
Following the deal, Rexahn would own about 28% of Future Systems, an information technology company that's expanding into the pharmaceutical business (4/24) |
Symyx |
3D Systems Corp. |
Deal to discover advanced materials with improved properties for use in 3D's prototyping and manufacturing solutions |
3D will fund research by Symyx and will have exclusive rights to commercialize resulting materials; Symyx would get royalties on resulting sales (4/26) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
OTC BB = Over-the-Counter Bulletin Board. | |||
